A Comprehensive Single-Cell and Spatial Analysis of Macrophage States in Human Atherosclerotic Plaques - Top-Institutions - MDSpire

A Comprehensive Single-Cell and Spatial Analysis of Macrophage States in Human Atherosclerotic Plaques

  • By

  • Yuanyuan Yang

  • Haiying Zhu

  • April 29, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Cardiovascular Medicine
    • Immunology
    • Genomics
    • Computational Biology

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Cardiology
    • Immunology
    • Molecular Biology

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Cardiovascular Medicine
    • Immunology
    • Pathology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Cardiology
    • Immunology
    • Genomics

  • #5

    Massachusetts General Hospital (MGH) / Harvard Medical School
    Massachusetts General Hospital (MGH) / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Cardiology
    • Immunology
    • Molecular Medicine

Original Source(s)

A Comprehensive Single-Cell and Spatial Analysis of Macrophage States in Human Atherosclerotic Plaques

  • by Yuanyuan Yang, Haiying Zhu

  • April 29, 2026

Related Content

Long COVID May Raise Cardiovascular Risk

Population-based cohort shows higher rates of cardiac arrhythmias and coronary artery disease following nonhospitalized infections, with sex-specific differences.

IVC Filters Show Mixed Outcomes in APE

Evidence synthesis highlights reduced embolism risk but persistent safety concerns and no survival benefit.

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.